Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda

Erisa Sabakaki Mwaka; Ian Guyton Munabi; Barbara Castelnuovo; Arvind Kaimal; William Kasozi; Andrew Kambugu; Philippa Musoke; Elly Katabira

doi:10.1371/journal.pone.0246389

. 2021 Feb 5;16(2):e0246389. doi: 10.1371/journal.pone.0246389

Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda

Erisa Sabakaki Mwaka ^1,^2,^*, Ian Guyton Munabi ¹, Barbara Castelnuovo ², Arvind Kaimal ², William Kasozi ², Andrew Kambugu ¹, Philippa Musoke ³, Elly Katabira ⁴

Editor: Osama Farouk⁵

PMCID: PMC7864439 PMID: 33544754

Abstract

Background

This study set out to determine the prevalence of low bone mass following long-term exposure to antiretroviral therapy in Ugandan people living with HIV.

Methods

A cross-sectional study was conducted among 199 people living with HIV that had been on anti-retroviral therapy for at least 10 years. All participants had dual X-ray absorptiometry to determine their bone mineral density. The data collected included antiretroviral drug history and behavioral risk data Descriptive statistics were used to summarize the data. Inferential statistics were analyzed using multilevel binomial longitudinal Markov chain Monte Carlo mixed multivariate regression modelling using the rstanarm package.

Results

One hundred ninety nine adults were enrolled with equal representation of males and females. The mean age was 39.5 (SD 8.5) years. Mean durations on anti-retroviral treatment was 12.1 (SD 1.44) years, CD4 cell count was 563.9 cells/mm³. 178 (89.5%) had viral suppression with <50 viral copies/ml. There were 4 (2.0%) and 36 (18%) participants with low bone mass of the hip and lumbar spine respectively. Each unit increase in body mass index was associated with a significant reduction in the odds for low bone mineral density of the hip and lumbar spine. The duration on and exposure to the various antiretroviral medications had no significant effect on the participant’s odds for developing low bone mass. All the coefficients of the variables in a multivariable model for either hip or lumbar spine bone mass were not significant.

Conclusion

These results provide additional evidence that patients on long term ART achieve bone mass stabilization. Maintaining adequate body weight is important in maintaining good bone health in people on antiretroviral therapy.

Introduction

Globally, nearly 70% of the people living with the human immunodeficiency virus (HIV), which is an estimated 37.9 million people, are in Sub-Saharan Africa (SSA) [1]. As of June 2019, 24.5 million people were accessing antiretroviral therapy and currently the World Health Organization (WHO) recommends that all HIV infected individuals should be initiated on ART upon diagnosis [2]. The wide spread use of antiretroviral therapy (ART) to treat HIV infection has led to increased lifespans of HIV-infected persons and a marked reduction in AIDS associated complications but created additional health challenges related to aging with HIV [3,4].

The burden of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) is higher than the global average; and should therefore be prioritized on the health and development agenda [5]. Non-communicable diseases are becoming a leading cause of morbidity and mortality also in the HIV-infected populations especially those on long-term anti-retroviral therapy (ART) [6]. Long-term use of ART has been associated with several adverse effects on bone mineral density (BMD) that call for continual monitoring, especially now that a sizable proportion of Ugandan people living with HIV (PLWH) have been on ART for long durations. It is important to note that 67% of adults living with HIV are accessing ART in eastern and southern Africa [1] with a sizable proportion of these being on ART for over a decade [6], yet relatively little is known about the impact of ART on bone health.

The prevalence of low BMD in PLWH and ART-treated individuals is reported to be twice that in health individuals [7]. The prevalence of osteopenia and osteoporosis in PLWH ranges from 48% to 55% and 10% to 34% respectively [8,9] with HIV-infected individuals having a 6.3 times greater chance of developing low BMD when compared to the HIV-uninfected, and HIV infected individuals on ART-treated having a 2.5 times greater risk of developing low BMD compared to the ART-naïve individuals [3]. Results form a meta-analysis [7] showed that HIV infected individuals had twice the risk of developing hip and lumbar spine low BMD (odds ratio 2.4 and 2.6 respectively), compared to the HIV-uninfected. In the same meta-analysis, the odds of developing low BMD at the hip and lumbar spine was 2.8 times (p = 0.004) and 3.4 times (p = 0.0002) respectively when compared to ART-naïve individuals.

Generally, BMD is higher among PLWH in low and middle-income countries (LMIC) compared to resource rich settings with prevalence rates as high as 85% [10–14]. Data from developed countries consistently show that HIV infection is associated with low BMD and an increased fracture risk, however, there is limited published data from resource limited settings (RLS) on longitudinal changes in BMD, the effect of ART regimens on BMD and almost no data on fragility fractures among HIV infected individuals. This could be attributed to bone health not being a priority in these settings, limited availability of dual energy X-ray absorptiometry (DXA) machines and the prohibitive cost of DXA scanning in most SSA countries [14].

The risk factors for low BMD in the developed world remain similar to those in RLS [8,15,16]. However, some of these risk factors such as low body mass index (BMI), malnutrition, advanced disease, longer duration of disease and a higher viral load are more prevalent in RLS [10,11,17,18]. The prevalence of low BMD in the Ugandan population is not known. Furthermore, there are no local guidelines for the diagnosis and management of osteoporosis in the country. This study therefore set out to determine the prevalence and predictors of low BMD following long-term exposure to ART in Ugandan PLWH.

Much as many studies with relatively young populations [8,9,17,19] use the World Health Organization criteria for categorizing bone loss, in this study we used the International Society of Clinical Densitometry (ISCD) official position that recommends the use of “Bone mass” instead of “Bone mineral density” for pre-menopausal females, males younger than 50 years and children [20].

Materials and methods

Study design and setting

This was a cross-sectional study conducted over an 18 month period in a cohort of PLWH receiving treatment from the Makerere University Infectious Diseases Institutes (IDI) HIV care clinics in Kampala, the capital city of Uganda. The IDI is a Center of Excellence for HIVAIDS research and service delivery in Uganda [21]. The clinic opens 10 hours a day, 5 days a week and currently supports the care for over 8,000 HIV/AIDS clients.

The study population comprised of adult PLWH, who are part of the IDI Antiretroviral Treatment Long-term (ALT) cohort, which has been enrolling patients receiving ART consecutively for at least 10 years and plan to follow them up for another 10 years. The ALT cohort currently comprises 1000 individuals who have been undergoing annual evaluations for more than 10 years. Details of the ALT cohort have been published and described elsewhere [22]. Using randomly generated computer numbers we randomly enrolled adults above 18 years who had been receiving ART for at least 10 years and were willing and able to comply with all study procedures. We excluded clients who were hospitalized or bedridden, enrolled in clinical trials, those with pathological fractures, history of trauma or surgery at the measurement site and those that were unwilling or unable to comply with any part of the study protocol. One hundred ninety nine PLWH were enrolled in the study (Fig 1).

The sample size was calculated using the www.openepi.com online proportions sample size calculator for: an 80.4% prevalence of low BMD among HIV positive persons on ART [11], population size of 1000 HIV positive clients on ART, confidence limits of 5% and design effect of 1.3 arising from the multiple medications for each client at any one time to give a calculated sample size of 190 respondents for a power of 90. To this was included a 5% allowance for loss and omissions, binging the final sample size to 200 respondents.

Participants were consecutively recruited over the 18-month study period. Clients were invited to participate and enrolled during their routine annual clinic visit.

Study procedures

All participants were subjected to lumbar spine, left total hip and left femoral neck body scans, to assess body mineral content and bone mineral density (BMD), using dual energy X-ray absorptiometry (DXA) (Hologic Discovery Wi Apex 3.1, Hologic Bedford Inc., Bedford, MA, USA) using standard protocols. Bone mineral density was expressed in grams of mineral per square centimetre. The reference population for this scanning was age, sex, race and BMI matched from the National Health and Nutrition Examination Survey (NHANES) cohort [23]. Bone mass was categorized using the official position of the International Society of Clinical Densitometry (ISCD) since most participants were below 50 years of age [20]. The ISCD official position recommends the use of the Z-score for pre-menopausal females, males younger than 50 years and children. A Z-score of -2.0 or lower was defined as having low bone mass for age and a Z-score above -2.0 was defined as bone mass within the expected range for age [20]. The World Health Organization (WHO) was used for post-menopausal females and males above 50 years of age [24,25]. A T-score that was within one standard deviation (SD) of the reference BMD was classified as normal, 1 to 2.5 SD below the reference BMD as osteopenia, and greater than 2.5 SD below the reference BMD as osteoporosis. For this study all participants with low bone mass or osteopenia/osteoporosis were categorized as having “low bone mass” while the rest were categorized as having normal bone mass (BM). This was done for ease of data analysis. The following data was also collected at enrolment: age, sex, height and weight for use in calculating Body Mass Index (BMI), the type of ART (categorized as Nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and Integrase inhibitors), duration on specific antiretroviral agents, behavioural risk information including alcohol and tobacco use, and history of previous fractures of the wrist, hip or spine, using a study questionnaire and data abstraction tool.

Data collection and statistical analysis

Data were collected initially collected using case report forms and then entered into DataFax forms that were specially designed for this study. This data management system is designated to manage paper data forms. The forms are faxed to the DataFax server where they are read using intelligent characters-recognition and then added to the study database. The latest viral load results and nadir CD4 count were retrieved from the Integrated Clinic Enterprise Application (ICEA) database, an in-house software that provides good quality data collection, with minimal missing or incorrect information [26]. These validated records were then exported as excel files for transformation so that each row represented an individual drug exposure prior to further analysis in the R-statistical computing environment [27]. The final long dataset comprised of 1384 anti-retroviral drug exposures. The analysis was informed by the study hypothesis that: exposure (time on treatment and type of drugs) to ART was associated with differences in BM among respondents after controlling for age, alcohol consumption, sex, smoking, most recent viral load, CD4 cell count, line of treatment (switch) and body mass index. During analysis descriptive statistics were generated and summarised as frequencies and correlations in tables. Inferential statistics were generated with multilevel binomial longitudinal Markov chain Monte Carlo (MCMC) mixed multivariate regression modelling using the rstanarm package [28–30]. The diagnostics for each model, one for the spine and other for hip BM, were used to identify any poorly performing values and assess the sampling quality. The absence of a value of “zero” in the 95% confidence interval for the coefficients was used to identify statistically significant output values. The mean coefficients were summarised in tables but exponentiated to obtain odds ratios. All records with missing data were removed from the database prior to the inferential MCMC part of the analysis. Ethics approval was obtained from the Makerere University School of Biomedical Sciences Higher Degrees and Research Ethics Committee (SBSHDREC 410) and the Uganda National Council of Science and Technology (HS 2179). All participants provided informed consent to participate in the study.

Results

One hundred ninety nine PLWH were recruited between July 2017 and July 2018. Fewer participants (4/199, 2%) had left hip low bone mass compared to the lumbar spine (36/199, 18%) as shown in Table 1. There was equal representation of both males (50%) and females (50%). The mean age was 39.5 (SD 8.5) years and female participants were on average younger than male participants by 1.38 years (standard error = 1.21, t-value = -1.14, P-value = 0.25). At the time of recruitment, participants had on average been living with HIV for 12.6 (SD 1.55) years since diagnosis and a mean of 12.1 (SD 1.44) years on ART. One hundred seventy eight (89.5%) of the participants had viral suppression with <50 viral copies/ml. The mean CD4 cell count was 564 cells/mm³ (SD 20.4, CI 524–604).

Table 1. Descriptive statistics for the study population.

Variable	Observation	Total (%)
Age	Mean (SD)	39.4 (8.5)
Female gender	Yes	100 (50.3)
Female gender	No	99 (49.7)
Alcohol consumption	Yes	37 (18.6)
Alcohol consumption	No	162 (81.4)
Smoke	No	177 (88.9)
Smoke	Yes	22 (11.1)
Left Hip BM	Low BMD	4 (2.0)
Left Hip BM	Normal	195(98.0)
Lumbar Spine BM	Low BMD	36 (18.1)
Lumbar Spine BM	Normal	163 (81.9)
Body Mass Index^*	Normal weight	108 (55.1)
	Overweight	57 (29.1)
	Obese	16 (8.2)
	Under weight	15 (7.7)
Viral load	Mean (SD)	19568.8 (77277.2)
	Suppressed	178 (89.45)
	Not-Suppressed	21 (10.55)

Open in a new tab

*The WHO general cut off points for BMI classification were used for this study however literature suggests that they may vary with race/ethnicity and between countries [31–33].

The correlations between the study variables as summarized in Table 2, were moderate to weak. There was moderate correlation for observed low BM between the hip and the lumbar spine (R = 0.30, P-value = <0.01).

Table 2. Showing the correlations between the study variables.

	Age	Gender	Alcohol	Smoking	Lumbar BM	Left Hip BM	Body mass index	Viral suppression
Age
Gender	-0.08
Alcohol	0.01	-0.01
Smoking	0.16*	0.13	0.24***
Lumbar BM	0.19**	0.21**	-0.09	-0.08
Left hip BM	-0.05	0.00	-0.07	0.05	0.30****
Body mass index	0.09	0.13	0.05	-0.07	0.02	-0.07
Viral suppression	-0.02	0.02	-0.04	-0.02	-0.03	-0.05	-0.06
CD4	0.08	0.13	-0.03	-0.05	0.11	0.05	0.10	0.25**

Open in a new tab

Stars Key: p < .0001, “****”, p < .001, “***”, p < .01, “**”, p < .05, “*”.

Fig 2 provides a summary of the different ART drug classes in the various prescriptions for each participant, from the time of initiation on ART till recruitment into the study. From this table non-reverse transcriptase inhibitors (NRTI) were the most commonly prescribed medications.

There were three incomplete participants records 4/199 (2%), which were excluded, leaving 196 complete respondents’ records for further analysis.

Table 3 provides a summary of the best-fitted univariable and multivariable MCMC models for BMI determined using hip BM and lumbar spine BM. Overall on the univariable analysis, each unit change in the classification of BMI was associated with a large reduction in the odds for low BM. This was significant for both the hip (OR = 0.06, 95% CI 0.01 to 0.47) and lumbar spine (OR = 0.004, 95% CI 0.0002 to 0.07). Also, in this table note that, for both hip (OR = 70.11, 95% CI 1.75 to 3,071) and lumbar spine (OR = 14,185, 95% CI 20.70 to 18,255,921), participants who were underweight were several times more likely to have a low BM compared to the normal weight participants. On the other hand, participants who were overweight were less likely to have low BM. This was significant for the lumbar spine observations (OR = 0.002, 95% CI <0.01 to 0.29). Also, either being female or each unit increase in age was associated with significantly lower odds of low BM on univariable modeling. All the coefficients for the variables of the best multivariable model for both hip and lumbar spine BM were not significant. As shown in Table 3, for both the univariable and multivariable modeling, the duration on and exposure to the various ART medications had no significant effect on the participant’s odds for developing low BM. For the multivariable model interactions in Table 3, it is important to note that the interaction between being female and having ever smoked was associated with significantly lower odds for observed low BM affecting the lumbar spine (OR<0.01, 95% CI <0.01 to 0.04).

Table 3. Univariable and multivariable bone mass models.

	Univariate models		Multivariate Model
	Mean (SD)	95% CI	Mean (SD)	95% CI	N-Eff
Dependent: Hip BM
Duration on drug	0.52 (1.96)	-3.34 to 4.52	0.77 (2.09)	-3.39 to 4.88	36670
ART drug prescriptions	0.00 (0.08)	-0.16 to 0.16	0.00 (0.08)	-0.16 to 0.17	52303
Switch	-0.18 (0.50)	-0.78 to 1.20	0.10 (0.56)	-1.00 to 1.22	40584
Age	-4.39 (4.79)	-14.24 to 4.79	-3.56 (5.72)	-15.01 to 7.43	26296
Gender as female	0.14 (1.45)	-2.70 to 2.99	0.52 (5.27)	-9.89 to 10.84	25320
Latest CD4 cell count	-2.75 (4.12)	-11.27 to 5.08	-10.19 (15.30)	-40.78 to 19.82	24117
Alcohol	3.08 (2.66)	-1.34 to 9.04	3.00 (3.20)	-2.43 to 10.21	24362
Ever smoked (yes)	-3.63 (3.64)	-11.92 to 2.20	3.75 (16.50)	-31.10 to 35.16	23220
Virus suppressed (yes)	3.56 (3.72)	-2.37 to 12.09	8.24 (16.04)	-21.85 to 41.85	23331
Body mass index (BMI)	-2.80 (1.10)	-5.07 to -0.74^*	-2.59 (6.30)	-15.01 to 7.43	23168
Under weight	4.25 (1.87)	0.56 to 8.03^*	-	-	-
Normal weight (reference)	1	1	-	-	-
Overweight	-2.24 (2.17)	-6.91 to 1.57	-	-	-
Obese	-3.65 (4.34)	-14.00 to 3.12	-	-	-
Interactions
Age and ever smoked (yes)	-	-	-2.93 (26.02)	-59.14 to 42.59	22631
Ever smoked and female gender	-	-	-1.60 (9.32)	-20.53 to 16.48	23201
Ever smoked and Alcohol	-	-	-5.15 (8.41)	-22.61 to 11.08	24341
Gender as female and BMI	-	-	0.05 (2.48)	-4.74 to 4.97	23961
Yes virus suppressed and BMI	-	-	-2.02 (5.93)	-13.46 to 10.10	23435
CD4 and BMI	-	-	4.16 (6.88)	-9.66 to 17.38	23341
Dependent: Lumbar BM
Duration on drug	-0.58 (1.84)	-3.04 to 4.11	0.72 (1.95)	-3.14 to 4.60	31708
ART drug	0.01 (0.06)	-0.13 to 0.12	-0.00 (0.07)	-0.14 to 0.14	41214
Switch	-0.10 (0.51)	-1.12 to 0.89	-0.14 (0.56)	-1.26 to 0.95	36627
Age	-15.26 (6.77)	-29.16 to -2.43^*	-14.07 (7.69)	-29.43 to 0.84	13522
Gender as female	-5.65 (2.05)	-9.82 to -1.76^*	-4.01 (7.47)	-19.09 to 10.47	12560
Latest CD4 cell count	-7.32 (5.88)	-19.10 to 4.06	-19.93 (23.92)	-71.26 to 22.80	16327
Alcohol	3.03 (2.79)	-2.38 to 8.68	2.67 (3.36)	-3.85 to 9.45	14144
Ever smoked (yes)	3.56 (3.15)	-2.65 to 9.66	22.71 (16.59)	-9.30 to 55.92	14947
Virus suppressed (yes)	1.57 (3.52)	-5.15 to 8.56	-3.57 (16.02)	-35.37 to 27.28	16868
Body mass index	-5.47 (1.43)	-8.45 to -2.71^*	-4.47 (6.15)	-16.94 to 7.18	15852
Under weight	9.56 (3.46)	3.03 to 16.72^*	-	-	-
Normal weight (reference)	1	1	-	-	-
Overweight	-6.07 (2.49)	-11.05 to -1.25^*	-	-	-
Obese	-5.61 (4.09)	-14.03 to 1.92	-	-	-
Interactions
Age and ever smoked	-	-	-42.97 (32.41)	-110.02 to 15.76	16057
CD4 cell & virus suppressed	-	-	19.93 (24.78)	-24.88 to 72.83	16712
Alcohol and ever smoked	-	-	-0.96 (7.26)	-15.12 to 13.51	13729
Ever smoked and female yes	-	-	-22.28 (10.24)	-43.09 to -3.16^*	15585
Viral suppression and BMI	-	-	-0.26 (5.96)	-11.56 to 11.94	16578
BMI and Gender as female	-	-	0.15 (3.16)	-5.95 to 6.45	13065

Open in a new tab

* P< 0.05.

Discussion

In this cross-sectional study we observed that the duration of exposure to ART medication and ART classes have no significant effect on participants’ risk for developing low BM and that high BMI is associated with reduced risk of developing low BMD in PLWH on long-term ART. People living with HIV are at increased risk of developing low BM when compared to age-matched HIV uninfected controls [34,35]. In this study, there were more cases of low BM as defined by the lumbar spine than the hip by a factor of 9. The prevalence of low BM was 18.1%. The prevalence of low BM in our study is consistent with what is reported in literature [8,9,17,19]. It is important to note that most longitudinal studies reporting on bone health in PLWH on long term ART use the WHO criteria for categorizing BMD instead of the ISCD official position that recommend the use of BM instead of BMD; despite having relatively young populations.

The ISCD also asserts that osteoporosis cannot be diagnosed in men under 50 years of age using BMD alone [20]. Therefore in the absence of local national guidance on the diagnosis and management of osteoporosis, we considered the official position of the International Society of Clinical Densitometry (ISCD) to categorize participants as having low BM or normal bone, since most participants were below 50 years of age [20]. However, the WHO criteria were also used to categorize post-menopausal females and males above 50 years. For ease of analysis, those categorized as osteopenia or osteoporosis were grouped together and considered as having low BM. The official position of International osteoporosis foundation (IOF) recommends BMD measurements at both the lumbar spine and the hip, and to use the lowest BMD recorded [36–39]. The IOF official position further recommends that lumbar spine BMD be used for monitoring response to treatment while hip BMD is considered the best predictor for hip fractures [40].

The prevalence of low BM in our study is consistent with what was previously reported in a study conducted at our institution to investigate low BMD among patients failing first-line ART, though the mean duration on antiretroviral medication at the time was only 3.7 years [17]. With a mean ART experience of more than 12 years, we believe that our participants had stable BM. Antiretroviral therapy has been shown to significantly contribute to low BM irrespective of classes [9,10,14,41–43]; although this accelerated bone loss has been mainly associated with tenofovir disoproxil fumarate (TDF) containing regimens compared to non-TDF-containing regimens [14,43–45]. This initial bone loss is transient, possibly due to increased bone catabolism after viral load suppression and immune reconstitution [46–49], and has been shown to be most marked in the first two years of ART initiation with about 2–6% loss in BMD [50] followed by a long period of stable BMD or increase [51,52]. These changes in BMD over time have been shown to be comparable to those in uninfected health controls [51]. The pathogenesis of increased bone turn over in HIV infected individuals is rather complex and multifactorial [7]. HIV infection per se increases inflammatory cytokines that are thought to increase bone turn-over through the stimulation of osteoclast and bone resorption [7,53]. The mechanism of action of anti-retroviral drugs on low BM remains controversial [3,12]. Evidence from longitudinal data shows that among the different antiretroviral drugs, tenofovir is associated with bone loss [45,54–58] and this has been attributed to increased bone turnover. The exact mechanism by which TDF reduces bone mass is yet to be elucidated but, some studies have linked it to proximal renal tubular dysfunction [59–62] with possible resultant impairment in Vitamin D metabolism [59,61,63,64]. Protease inhibitors have been reported to suppress osteoclast function [65]. Several cross-sectional studies from LMIC have shown an association between non-nucleoside reverse transcriptase inhibitors (NNRTIs) particularly Efavirenz, which is widely used to treat HIV in LMIC, and low 25-hydroxyvitamin D [66–69]. Low levels of Vitamin D have been associated with a higher risk of HIV disease progression, death and virologic failure after ART [70–72]. Sub-optimal Vitamin D levels and cumulative exposure of tenofovir and protease inhibitors like lopinavir/ritonavir (LVP/RTV) have also been reported to independently increase the risk of low BMD [72,73] and fragility fractures [74]. TDF has been associated with a bigger decline in BMD than stavudine [55] or abacavir [45].

In the setting of long term viral suppression, understanding the complications of HIV infection and ART is paramount to successful management of HIV and its associated complications like low Bone mineral density [9]. Our findings further suggest that the duration of exposure to the various ART classes, is not associated with low BM; which is consistent with other studies which have reported stable BMD in PLWH on long-term ART [44,51,52,75–78], suggesting a long-term benefit of antiretroviral therapy. Bolland et. al [52] reported stable BMD in a cohort of 44 HIV infected middle-aged men on ART who were followed up for up to12 years. They further reported a BMD increase of 6.9% at the lumbar spine; and actually argued that it was not necessary to follow up men established on ART who do not have risk factors for BMD loss. Important to note, is the 5% mean increase in weight over the 12 years in their cohort. Increase in weight reduces the odds of developing low BMD, which is consistent with what was observed in our study. Bone loss is influenced by several factors including body weight, age, physical activity level, diet to mention a few [79]. Low BMI is a well-documented risk factor for osteoporosis and hip fractures in both men and women [10,80]. Weight loss is associated with 1% to 2% bone loss at the hip [81–83] and has been associated with bone mobilization and decrease in bone mineral content and BMD [84–86]. Therefore it is important for on ART to maintain adequate weight if they are to maintain good bone health.

In the setting of long term viral suppression, understanding the complications of HIV infection and ART is key to successful management of HIV and its associated complications [9]. We hope our results will raise awareness on bone health among clinicians and contribute to appropriate planning and management of low BMD among PLWH with the ultimate goal of making significant contribution towards reducing the NCD burden among this population.

Strength of the study

The study was conducted among a well-characterized and organized cohort that had been consistently followed up every six months since 2004 and there was equal representation of both males and females. Secondly, all BMD scans were performed using the same machine and by the same technicians. Lastly, we utilized both Z-score and T-scores to diagnose low BMD in participants < 50 years and those above 50 years respectively as recommended by WHO [24,25].

Limitations

This was a cross-sectional study conducted at one site; therefore, the study findings might not be generalizable to PLWH in the general population. Secondly, our results are based on only one DXA scan, participants had uniform exposure to ART and there was no control group; thus making it difficult to make any inferences on the effect of individual anti-retroviral drugs and regimens on bone loss.

Conclusion

These results provide additional evidence that patients on long term ART achieve BM stabilization. It is important for PLWH on ART to maintain adequate weight if they are to maintain good bone health. There is need to develop local guidelines and protocols for the prevention and treatment of low bone mass not only in HIV, but also in the general public.

Acknowledgments

We are very grateful to our research participants for their voluntary participation in this study.

Data Availability

All data files are available from the Figshare database (DOI:10.6084/m9.figshare.13174628).

Funding Statement

This work was supported by University of Alabama at Birmingham (UAB) Center For AIDS Research in the form of a grant awarded to ESM (000503356-SP002-24), which was a sub-award from a National Institutes of Health grant awarded to Principal Investigator Michael Saags (P30AI027767-28). Janssen pharmaceutical company provided support through a Johnson & Johnson corporate citizenship trust used to partly fund the ALT cohort at the Infectious Disease Institute-Uganda. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1.HIV/AIDS JUNPo. Fact Sheet—Latest Global and Regional Statistics on the Status of the HIV Epidemic. 2019.
2.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach.: World Health Organization; 2016 [Second:[https://www.who.int/hiv/pub/arv/arv-2016/en/. [PubMed]
3.Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. Aids. 2006;20(17):2165–74. 10.1097/QAD.0b013e32801022eb [DOI] [PubMed] [Google Scholar]
4.Battalora LA, Young B, Overton ET. Bones, fractures, antiretroviral therapy and HIV. Current infectious disease reports. 2014;16(2):393 10.1007/s11908-014-0393-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990–2017: results from the Global Burden of Disease Study 2017. The Lancet Global Health. 2019;7(10):e1375–e87. 10.1016/S2214-109X(19)30374-2 [DOI] [PubMed] [Google Scholar]
6.Kiragga AN, Mubiru F, Kambugu AD, Kamya MR, Castelnuovo B. A decade of antiretroviral therapy in Uganda: what are the emerging causes of death? BMC infectious diseases. 2019;19(1):77 10.1186/s12879-019-3724-x [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Goh S, Lai PSM, Tan ATB, Ponnampalavanar S. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporosis International. 2018;29(3):595–613. 10.1007/s00198-017-4305-8 [DOI] [PubMed] [Google Scholar]
8.Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. Aids. 2010;24(18):2827–33. 10.1097/QAD.0b013e328340a28d [DOI] [PubMed] [Google Scholar]
9.Escota GV, Mondy K, Bush T, Conley L, Brooks JT, Önen N, et al. High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy. AIDS research and human retroviruses. 2016;32(1):59–67. 10.1089/aid.2015.0158 [DOI] [PubMed] [Google Scholar]
10.Alonge T, Okoje-Adesomoju V, Atalabi O, Obamuyide H, Olaleye D, Adewole I. Prevalence of abnormal bone mineral density in HIV-positive patients in Ibadan, Nigeria. Journal of the West African College of Surgeons. 2013;3(4):1 [PMC free article] [PubMed] [Google Scholar]
11.Dravid A, Kulkarni M, Borkar A, Dhande S. Prevalence of low bone mineral density among HIV patients on long-term suppressive antiretroviral therapy in resource limited setting of western India. Journal of the International AIDS Society. 2014;17(4). 10.7448/IAS.17.4.19567 [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. The Brazilian Journal of Infectious Diseases. 2013;17(6):707–11. 10.1016/j.bjid.2013.05.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Neto LFP, Ragi-Eis S, Vieira NF, Soprani M, Neves MB, Ribeiro-Rodrigues R, et al. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. Journal of Clinical Densitometry. 2011;14(4):434–9. 10.1016/j.jocd.2011.06.004 [DOI] [PubMed] [Google Scholar]
14.Matovu FK, Wattanachanya L, Beksinska M, Pettifor JM, Ruxrungtham K. Bone health and HIV in resource-limited settings: a scoping review. Current Opinion in HIV and AIDS. 2016;11(3):306–25. 10.1097/COH.0000000000000274 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Yin MT, Overton ET. Increasing clarity on bone loss associated with antiretroviral initiation. Journal of Infectious Diseases. 2011;203(12):1705–7. [DOI] [PubMed] [Google Scholar]
16.Kim H-S, Chin BS, Shin H-S. Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine. Journal of Korean medical science. 2013;28(6):827–32. 10.3346/jkms.2013.28.6.827 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Wandera B, Kiragga A, Semitala F, Ellis J, Colebunders R, Paton N, et al. Low Bone Mineral Density among Ugandan HIV infected patients on failing first line Antiretroviral Therapy; a sub-study of the EARNEST trial. Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections Boston, MA March 3–6, 2014 Boston, MA: National AIDS Treatment Advocavy project; 2014 [http://www.natap.org/2014/CROI/croi_65.htm.
18.Masyeni S, Utama S, Somia A, Widiana R, Merati TP. Factors influencing bone mineral density in ARV-naive patients at Sanglah Hospital, Bali. Acta Med Indones. 2013;45(3):175–9. [PubMed] [Google Scholar]
19.Chisati EM, Constantinou D, Lampiao F. Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors. PloS one. 2020;15(1):e0227893 10.1371/journal.pone.0227893 [DOI] [PMC free article] [PubMed] [Google Scholar]
20.2019 ISCD Official Positions: Adult: International Society for Clinical Densitometry; 2019 [https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/.
21.Nwaka S, Ochem A, Besson D, Ramirez B, Fakorede F, Botros S, et al. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent. BMC international health and human rights. 2012;12(1):11 10.1186/1472-698X-12-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Castelnuovo B, Kiragga A, Musaazi J, Sempa J, Mubiru F, Wanyama J, et al. Outcomes in a cohort of patients started on antiretroviral treatment and followed up for a decade in an urban clinic in Uganda. PloS one. 2015;10(12):e0142722 10.1371/journal.pone.0142722 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.National Health and Nutrition Examination Survey (NHANES) [https://www.cdc.gov/nchs/nhanes/index.htm.
24.Czerwiński E, Badurski J, Marcinowska-Suchowierska E, Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortopedia, traumatologia, rehabilitacja. 2006;9(4):337–56. [PubMed] [Google Scholar]
25.WHO, editor World Health Organisation (WHO) scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report; 2004.
26.Castelnuovo B, Kiragga A, Afayo V, Ncube M, Orama R, Magero S, et al. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa. PloS one. 2012;7(12):e51631 10.1371/journal.pone.0051631 [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Fox J, Andersen R. Using the R statistical computing environment to teach social statistics courses. Department of Sociology, McMaster University. 2005:2–4.
28.Goodrich B, Gabry J, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. 2018.
29.Bürkner P-C. Advanced Bayesian Multilevel Modeling with the R Package brms. The R Journal. 2018;10(1):395–411. [Google Scholar]
30.Bürkner P-C. brms: An R Package for Bayesian Multilevel Models Using Stan. Journal of Statistical Software. 2017;80(1):1–28. [Google Scholar]
31.Zhou B-F, China CM-AGotWGoOi. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and environmental sciences: BES. 2002;15(1):83 [PubMed] [Google Scholar]
32.Ogunlade O, Adalumo O, Asafa M. Challenges of body mass index classification: New criteria for young adult Nigerians. Nigerian Journal of Health Sciences. 2015;15(2):71. [Google Scholar]
33.Rahman M, Berenson AB. Accuracy of current body mass index obesity classification for white, black and Hispanic reproductive-age women. Obstetrics and gynecology. 2010;115(5):982 10.1097/AOG.0b013e3181da9423 [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893–7. 10.1016/j.bone.2005.11.001 [DOI] [PubMed] [Google Scholar]
35.Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS (London, England). 2009;23(12):1519 10.1097/QAD.0b013e32832c1792 [DOI] [PMC free article] [PubMed] [Google Scholar]
36.International OSteoporosis Foundation: Official positions Adults 2019 [https://iscd.app.box.com/s/5r713cfzvf4gr28q7zdccg2i7169fv86.
37.Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. Journal of Clinical Densitometry. 2004;7(1):1–5. 10.1385/jcd:7:1:1 [DOI] [PubMed] [Google Scholar]
38.Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM. Official positions of the International Society for Clinical Densitometry and executive summary of the 2005 Position Development Conference. Journal of Clinical Densitometry. 2006;9(1):4–14. 10.1016/j.jocd.2006.05.002 [DOI] [PubMed] [Google Scholar]
39.Kanis J, Cooper C, Rizzoli R, Reginster J-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3–44. 10.1007/s00198-018-4704-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Sheu A, Diamond T. Diagnostic tests: bone mineral density: testing for osteoporosis. Australian prescriber. 2016;39(2):35 10.18773/austprescr.2016.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, et al. Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis. Journal of acquired immune deficiency syndromes (1999). 2016;71(3):287 10.1097/QAI.0000000000000858 [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Collins BN, Levin KP, Bryant-Stephens T. Pediatricians’ practices and attitudes about environmental tobacco smoke and parental smoking. The Journal of pediatrics. 2007;150(5):547–52. 10.1016/j.jpeds.2007.01.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Grant PM, Cotter AG. Tenofovir and bone health. Current Opinion in HIV and AIDS. 2016;11(3):326 10.1097/COH.0000000000000248 [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. The Journal of infectious diseases. 2015;212(8):1241–9. 10.1093/infdis/jiv194 [DOI] [PMC free article] [PubMed] [Google Scholar]
45.McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. Journal of Infectious Diseases. 2011;203(12):1791–801. 10.1093/infdis/jir188 [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Bolland MJ, Grey A, Reid IR. Skeletal health in adults with HIV infection. The lancet Diabetes & endocrinology. 2015;3(1):63–74. 10.1016/S2213-8587(13)70181-5 [DOI] [PubMed] [Google Scholar]
47.Hoy JF, Grund B, Roediger M, Schwartz AV, Shepherd J, Avihingsanon A, et al. Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial. Journal of bone and mineral research. 2017;32(9):1945–55. 10.1002/jbmr.3183 [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clinical infectious diseases. 2013;57(10):1483–8. 10.1093/cid/cit538 [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Ofotokun I, Titanji K, Vikulina T, Roser-Page S, Yamaguchi M, Zayzafoon M, et al. Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nature communications. 2015;6(1):1–15. 10.1038/ncomms9282 [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Aids. 2009;23(7):817–24. 10.1097/QAD.0b013e328328f789 [DOI] [PubMed] [Google Scholar]
51.Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clinical endocrinology. 2012;76(5):643–8. 10.1111/j.1365-2265.2011.04274.x [DOI] [PubMed] [Google Scholar]
52.Bolland MJ, Horne AM, Briggs SE, Thomas MG, Reid IR, Gamble GD, et al. Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. Calcified tissue international. 2019;105(4):423–9. 10.1007/s00223-019-00579-0 [DOI] [PubMed] [Google Scholar]
53.Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk. Journal of Biological Chemistry. 2003;278(48):48251–8. 10.1074/jbc.M304676200 [DOI] [PubMed] [Google Scholar]
54.Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. The Lancet HIV. 2015;2(11):e464–e73. 10.1016/S2352-3018(15)00181-2 [DOI] [PubMed] [Google Scholar]
55.Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA: the journal of the American Medical Association. 2004;292(2):191–201. 10.1001/jama.292.2.191 [DOI] [PubMed] [Google Scholar]
56.Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–72. 10.1086/656417 [DOI] [PubMed] [Google Scholar]
57.Assoumou L, Katlama C, Viard J-P, Bentata M, Simon A, Roux C, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27(15):2425–30. 10.1097/QAD.0b013e32836378c3 [DOI] [PubMed] [Google Scholar]
58.Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, et al. Less bone loss with maraviroc-compared to tenofovir-containing antiretroviral therapy in the ACTG A5303 Study. Clinical Infectious Diseases. 2015:civ455. [DOI] [PMC free article] [PubMed] [Google Scholar]
59.Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, et al. Short communication Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antiviral therapy. 2008;13:1077–82. [PubMed] [Google Scholar]
60.Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Laboratory investigation. 2009;89(5):513–9. 10.1038/labinvest.2009.14 [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Aids. 2007;21(10):1273–81. 10.1097/QAD.0b013e3280b07b33 [DOI] [PubMed] [Google Scholar]
62.Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23(6):689–96. 10.1097/QAD.0b013e3283262a64 [DOI] [PubMed] [Google Scholar]
63.Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009;51(5):554–61. 10.1097/QAI.0b013e3181adce44 [DOI] [PubMed] [Google Scholar]
64.Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clinical Infectious Diseases. 2006;42(2):283–90. 10.1086/499048 [DOI] [PubMed] [Google Scholar]
65.Wang MW-H, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. The Journal of clinical investigation. 2004;114(2):206–13. 10.1172/JCI15797 [DOI] [PMC free article] [PubMed] [Google Scholar]
66.Steenhoff AP, Schall JI, Samuel J, Seme B, Marape M, Ratshaa B, et al. Vitamin D₃ supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial. PloS one. 2015;10(2):e0117123 10.1371/journal.pone.0117123 [DOI] [PMC free article] [PubMed] [Google Scholar]
67.Hidron AI, Hill B, Guest JL, Rimland D. Risk Factors for Vitamin D Deficiency among Veterans with and without HIV Infection. PloS one. 2015;10(4):e0124168 10.1371/journal.pone.0124168 [DOI] [PMC free article] [PubMed] [Google Scholar]
68.Wohl D, Doroana M, Orkin C, Pilotto J, Sungkanuparph S, Yeni P, et al., editors. Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial. 18th Conference on Retroviruses and Opportunistic Infections; 2011.
69.Wiboonchutikul S, Sungkanuparph S, Kiertiburanakul S, Chailurkit L-O, Charoenyingwattana A, Wangsomboonsiri W, et al. Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting. Journal of the International Association of Physicians in AIDS Care (JIAPAC). 2012:1545109711432142. [DOI] [PubMed] [Google Scholar]
70.Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder. BioMed research international. 2015;2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
71.Havers F, Smeaton L, Gupte N, Detrick B, Bollinger RC, Hakim J, et al. 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. Journal of Infectious Diseases. 2014;210(2):244–53. 10.1093/infdis/jiu259 [DOI] [PMC free article] [PubMed] [Google Scholar]
72.Dave JA, Cohen K, Micklesfield LK, Maartens G, Levitt NS. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans. PloS one. 2015;10(12):e0144286 10.1371/journal.pone.0144286 [DOI] [PMC free article] [PubMed] [Google Scholar]
73.Paul T, Asha H, Thomas N, Seshadri M, Rupali P, Abraham O, et al. Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy. Endocrine Practice. 2010. [DOI] [PubMed] [Google Scholar]
74.Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31. 10.1097/QAD.0b013e32835192ae [DOI] [PubMed] [Google Scholar]
75.Cassetti I, Madruga JVR, Suleiman JMA, Etzel A, Zhong L, Cheng AK, et al. The safety and efficacy of tenofovir df in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1—infected patients. HIV clinical trials. 2007;8(3):164–72. 10.1310/hct0803-164 [DOI] [PubMed] [Google Scholar]
76.Madeddu G, Spanu A, Solinas P, Babudieri S, Calia G, Lovigu C, et al. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2015;19(23):4576–89. [PubMed] [Google Scholar]
77.Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. Aids. 2001;15(10):1275–80. 10.1097/00002030-200107060-00009 [DOI] [PubMed] [Google Scholar]
78.Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. The Journal of Clinical Endocrinology & Metabolism. 2006;91(8):2938–45. 10.1210/jc.2006-0127 [DOI] [PMC free article] [PubMed] [Google Scholar]
79.Palermo A, Tuccinardi D, Defeudis G, Watanabe M, D’Onofrio L, Lauria Pantano A, et al. BMI and BMD: the potential interplay between obesity and bone fragility. International journal of environmental research and public health. 2016;13(6):544 10.3390/ijerph13060544 [DOI] [PMC free article] [PubMed] [Google Scholar]
80.De Laet C, Kanis J, Odén A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporosis international. 2005;16(11):1330–8. 10.1007/s00198-005-1863-y [DOI] [PubMed] [Google Scholar]
81.Langlois J, Mussolino M, Visser M, Looker A, Harris T, Madans J. Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study. Osteoporosis international. 2001;12(9):763–8. 10.1007/s001980170053 [DOI] [PubMed] [Google Scholar]
82.Ensrud KE, Fullman RL, Barrett-Connor E, Cauley JA, Stefanick ML, Fink HA, et al. Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study. The Journal of Clinical Endocrinology & Metabolism. 2005;90(4):1998–2004. 10.1210/jc.2004-1805 [DOI] [PubMed] [Google Scholar]
83.Bleicher K, Cumming RG, Naganathan V, Travison TG, Sambrook PN, Blyth FM, et al. The role of fat and lean mass in bone loss in older men: findings from the CHAMP study. Bone. 2011;49(6):1299–305. 10.1016/j.bone.2011.08.026 [DOI] [PubMed] [Google Scholar]
84.Compston J, Laskey M, Croucher P, Coxon A, Kreitzman S. Effect of diet-induced weight loss on total body bone mass. Clinical Science. 1992;82(4):429–32. 10.1042/cs0820429 [DOI] [PubMed] [Google Scholar]
85.Center JR, White CP. Obesity: bariatric surgery, weight loss and bone. Nature Reviews Endocrinology. 2013;9(11):630 10.1038/nrendo.2013.189 [DOI] [PubMed] [Google Scholar]
86.Meyer HE, Søgaard AJ, Falch JA, Jørgensen L, Emaus N. Weight change over three decades and the risk of osteoporosis in men: the Norwegian Epidemiological Osteoporosis Studies (NOREPOS). American journal of epidemiology. 2008;168(4):454–60. 10.1093/aje/kwn151 [DOI] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0246389.r001

Decision Letter 0

Osama Farouk

18 Sep 2020

PONE-D-20-22805

Bone mineral density in people living with the HIV on long term antiretroviral therapy in Uganda

PLOS ONE

Dear Dr. Mwaka,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please insert comments here and delete this placeholder text when finished. Be sure to:

Please respond to the three reviewers' comments and address them in the revised manuscript.
The decision of acceptance or rejection is justified on PLOS ONE’s publication criteria.

==============================

Please submit your revised manuscript by Nov 02 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Osama Farouk

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3.Thank you for stating the following in the Financial Disclosure section:

[This research was supported by a sub-award to ESM (grant number 000503356-SP002-24) from the University of Alabama at Birmingham (UAB) Center For AIDS Research (https://www.uab.edu/medicine/cfar/) a National Institutes of Health funded program (P30AI027767-28, PI Michael Saags) that was made possible by NIAID/NIH/DHHS. The ALT cohort at the Infectious Disease Institute-Uganda is partly funded by Janssen pharmaceutical company through Johnson & Johnson corporate citizenship trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.].

We note that you received funding from a commercial source: [Janssen pharmaceutical company]

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The survey does give the general picture of BMD among a well-represented 200 PLWD. Since only one BMD was taken, the data did not provide information about the trend of development, particularly among the group with low BMD. To give real clinical value to the survey, another BMD needs to be arranged in 2-3 years' time to identify the changes so as to allow some practical recommendations on the management.

Reviewer #2: -how were the participants selected? What were the inclusion criteria? A consort flow diagram would be very helpful.

-Ref 22/23 are not appropriate: most participants were under 50 years old. Therefore, the ISCD (not the WHO!) recommends to apply the Z-scores, not the T-scores. Low bone mass is defined as a Z-scores <-2.0 meaning that long-term ART is not associated with low BMD. The categorisation of the measurements should be provided: how many participants had actually a Z-score below -2.0?

-discussion: the recommendations for screening are not supported by the data shown.

-conclusion: please do not over interprete our findings: association does not mean causality!

Reviewer #3: Thank you for your submission. I have the following comments:

1. Abstract: "This study set out to determine the prevalence and predictors of low BMD following long-term exposure to antiviral therapy....".

It seems to me that you have evaluated the prevalence of low BMD in your study but the predictors of low BMD were only studied in a very limited manner as there was no inclusion of lifestyle, exercise levels, education level, socio-economical and comorbidity, etc. The original statement needs revision to describe your completed work.

2. The sampling: need more description on random or convenient sampling from your pool of 8000 (refers page 5, line 8).

3. Table 1: need to include Alcohol data in your disclosure. For the BMI definition of overweight and obese vary between different countries, suggest to list out clearly.

4. Table 3: suggest to add a bar chart presentation for clarity.

5. Table 4: need to improve the presentation, plus add more explanation and justification.

6. Having revised 1 to 5, the title of the paper could be modified to reflect your actual completed work.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Anthony WL KWOK, PhD

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 5;16(2):e0246389. doi: 10.1371/journal.pone.0246389.r002

Author response to Decision Letter 0

12 Nov 2020

Response to Editor

1. a) Comment: Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Response: The manuscript has been formatted and meets the PLOS ONE style.

b) Comment: If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Response: There are no ethical or legal restrictions to sharing a de-identified set of our data. The dataset has been submitted and published on Figshare, DOI:10.6084/m9.figshare.13174628.

c) Comment: If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers.

Response: This has been done.

2. Comment: We note that you received funding from a commercial source: [Janssen pharmaceutical company]. Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Response: This research was supported by a sub-award to ESM (grant number 000503356-SP002-24) from the University of Alabama at Birmingham (UAB) Center For AIDS Research (https://www.uab.edu/medicine/cfar/) a National Institutes of Health funded program (P30AI027767-28, PI Michael Saags) that was made possible by NIAID/NIH/DHHS. The ALT cohort at the Infectious Disease Institute-Uganda is partly funded by Janssen pharmaceutical company through Johnson & Johnson corporate citizenship trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We declare competing interest; Janssen pharmaceutical company provides financial support to the Antiretroviral Treatment Longterm (ALT) Cohort at the Infectious Diseases Institute-Uganda. However, this does not alter our adherence to PLOS ONE policies on sharing data and materials.

Response to reviewers

Reviewer #1

Comment: The survey does give the general picture of BMD among a well- represented 200 PLWD. Since only one BMD was taken, the data did not provide information about the trend of development, particularly among the group with low BMD. To give real clinical value to the survey, another BMD needs to be arranged in 2-3 years' time to identify the changes so as to allow some practical recommendations on the management

Response: We are very interested in longitudinal follow up of the bone health of these individuals and are therefore working on a grant application to include bone health as one of the routine annual follow up procedures for the cohort. If successful we hope to follow them up for up to 96 weeks.

Reviewer #2

Comment: How were the participants selected? What were the inclusion criteria? A consort flow diagram would be very helpful.

Response: We have added a statement “Using computer generated numbers we randomly enrolled adults above 18 years who had been receiving ART for at least 10 years and were willing and able to comply with all study procedures” Lines 87-89. We have also added a flow diagram as suggested.

Comment: Ref 22/23 are not appropriate: most participants were under 50 years old. Therefore, the ISCD (not the WHO!) recommends to apply the Z-scores, not the T-scores. Low bone mass is defined as a Z-scores <-2.0 meaning that long-term ART is not associated with low BMD. The categorisation of the measurements should be provided: how many participants had actually a Z-score below -2.0?

Response: We have re-analysed the data using the official position of the International Society of Clinical Densitometry (ISCD) since most participants were below 50 years of age. A Z-score of -2.0 or lower has been defined as having low bone mass for age and a Z-score above -2.0 has been defined as bone mass within the expected range for age. The World Health Organization has been used for post-menopausal females and males above 50 years of age. For ease of data analysis, all participants with low bone mass or osteopenia/osteoporosis have been categorized as having “low bone mass” while the rest are categorized as having normal bone mass (BM). The term “Bone Mass” has been adopted in place of “Bone Mineral Density”. 4/199 and 36/199 have either Z-scores below -2.0 or T-score below -1.0 for the hip and lumbar spine respectively.

The title has also been changed to “Low bone mass in people living with HIV on long-term anti-retroviral therapy in Uganda”

Comment: discussion: the recommendations for screening are not supported by the data shown.

Response: The recommendation on screening has been deleted.

Comment: conclusion: please do not over interpret our findings: association does not mean causality!

Response: The conclusion has been recast.

Reviewer #3

Comment: Abstract: "This study set out to determine the prevalence and predictors of low BMD following long-term exposure to antiviral therapy....".

Response: This has been revised to “This study set out to determine the prevalence of low bone mass following long-term exposure to antiretroviral therapy in Ugandan people living with HIV”.

Comment: The sampling: need more description on random or convenient sampling from your pool of 8000.

Response: A better description is given and a flow diagram included (Fig 1).

Comment: Table 1: need to include Alcohol data in your disclosure. For the BMI definition of overweight and obese vary between different countries, suggest to list out clearly.

Response: A statement had been added with appropriate references “The WHO general cut off points for BMI classification were used for this study however literature suggests that they may vary with race/ethnicity and between countries”.

Comment: Table 3: suggest to add a bar chart presentation for clarity.

Response: Table 3 has been replaced by a bar chart (Fig 2).

Comment: Table 4: need to improve the presentation, plus add more explanation and justification

Response: More information has been provided in the narrative to ease interpretation of Table 4 (Now Table 3).

Comment: 6. Having revised 1 to 5, the title of the paper could be modified to reflect your actual completed work.

Response: The title has been revised to “Low bone mass in people living with HIV on long-term anti-retroviral therapy in Uganda”.

Attachment

Submitted filename: Response to reviewer comments.docx

Click here for additional data file.^{(101.2KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0246389.r003

Decision Letter 1

Osama Farouk

24 Dec 2020

PONE-D-20-22805R1

Low bone mass in people living with the HIV on long term antiretroviral therapy in Uganda

PLOS ONE

Dear Dr. Mwaka,

==============================

Please, revise the title of the article as recommended by the reviewers.

==============================

Please submit your revised manuscript by Feb 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

We look forward to receiving your revised manuscript.

Kind regards,

Osama Farouk

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: The revised information have much improved the accuracy and quality of the first draft. The additional information in the tables and charts are relevant and clear that explains the original idea better.

As your study is a single centre study with all the data from the same centre, you can think about to fine tune the title further as below: Low bone mass in people living with the HIV on long term antiviral therapy: a single centre study in Uganda

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Leung Ping Chung

Reviewer #2: No

Reviewer #3: Yes: Anthony WL Kwok

PLoS One. 2021 Feb 5;16(2):e0246389. doi: 10.1371/journal.pone.0246389.r004

Author response to Decision Letter 1

30 Dec 2020

Comment: We note that you have included tables 1,2 and 4 but there is not Table 3, if this should be included then please include a copy within your manuscript and cite in your text. - or. If table 4 should actually be Table 3 then please amend the numbering of the table and citations within your text

Response: Thanks very much for this observation. Table 3 was mislabeled as Table 4. This has been rectified. “Table 4” now appears as “Table 3”.

Comment: Please amend the title either on the online submission form or in your manuscript so that they are identical.

Response: This has been done

Attachment

Submitted filename: Response to reviewer comments_R3.docx

Click here for additional data file.^{(56.3KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0246389.r005

Decision Letter 2

Osama Farouk

18 Jan 2021

Low bone mass in people living with HIV on long term antiretroviral therapy: a single centre study in Uganda

PONE-D-20-22805R2

Dear Dr. Mwaka,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Osama Farouk

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #3: Yes

**********

6. Review Comments to the Author

Reviewer #3: In your revised copy, you addressed all the issues that I have raised earlier. I have no additional comment to add. The title of the paper looks appropriate and accurate now.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: Yes: Anthony WL Kwok

PLoS One. doi: 10.1371/journal.pone.0246389.r006

Acceptance letter

Osama Farouk

28 Jan 2021

PONE-D-20-22805R2

Low bone mass in people living with HIV on long-term anti-retroviral therapy: a single centre study in Uganda

Dear Dr. Mwaka:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Osama Farouk

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Attachment

Submitted filename: Response to reviewer comments.docx

Click here for additional data file.^{(101.2KB, docx)}

Attachment

Submitted filename: Response to reviewer comments_R3.docx

Click here for additional data file.^{(56.3KB, docx)}

Data Availability Statement

All data files are available from the Figshare database (DOI:10.6084/m9.figshare.13174628).

[pone.0246389.ref001] 1.HIV/AIDS JUNPo. Fact Sheet—Latest Global and Regional Statistics on the Status of the HIV Epidemic. 2019.

[pone.0246389.ref002] 2.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach.: World Health Organization; 2016 [Second:[https://www.who.int/hiv/pub/arv/arv-2016/en/. [PubMed]

[pone.0246389.ref003] 3.Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. Aids. 2006;20(17):2165–74. 10.1097/QAD.0b013e32801022eb [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref004] 4.Battalora LA, Young B, Overton ET. Bones, fractures, antiretroviral therapy and HIV. Current infectious disease reports. 2014;16(2):393 10.1007/s11908-014-0393-1 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref005] 5.Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990–2017: results from the Global Burden of Disease Study 2017. The Lancet Global Health. 2019;7(10):e1375–e87. 10.1016/S2214-109X(19)30374-2 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref006] 6.Kiragga AN, Mubiru F, Kambugu AD, Kamya MR, Castelnuovo B. A decade of antiretroviral therapy in Uganda: what are the emerging causes of death? BMC infectious diseases. 2019;19(1):77 10.1186/s12879-019-3724-x [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref007] 7.Goh S, Lai PSM, Tan ATB, Ponnampalavanar S. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporosis International. 2018;29(3):595–613. 10.1007/s00198-017-4305-8 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref008] 8.Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. Aids. 2010;24(18):2827–33. 10.1097/QAD.0b013e328340a28d [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref009] 9.Escota GV, Mondy K, Bush T, Conley L, Brooks JT, Önen N, et al. High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy. AIDS research and human retroviruses. 2016;32(1):59–67. 10.1089/aid.2015.0158 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref010] 10.Alonge T, Okoje-Adesomoju V, Atalabi O, Obamuyide H, Olaleye D, Adewole I. Prevalence of abnormal bone mineral density in HIV-positive patients in Ibadan, Nigeria. Journal of the West African College of Surgeons. 2013;3(4):1 [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref011] 11.Dravid A, Kulkarni M, Borkar A, Dhande S. Prevalence of low bone mineral density among HIV patients on long-term suppressive antiretroviral therapy in resource limited setting of western India. Journal of the International AIDS Society. 2014;17(4). 10.7448/IAS.17.4.19567 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref012] 12.Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. The Brazilian Journal of Infectious Diseases. 2013;17(6):707–11. 10.1016/j.bjid.2013.05.009 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref013] 13.Neto LFP, Ragi-Eis S, Vieira NF, Soprani M, Neves MB, Ribeiro-Rodrigues R, et al. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. Journal of Clinical Densitometry. 2011;14(4):434–9. 10.1016/j.jocd.2011.06.004 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref014] 14.Matovu FK, Wattanachanya L, Beksinska M, Pettifor JM, Ruxrungtham K. Bone health and HIV in resource-limited settings: a scoping review. Current Opinion in HIV and AIDS. 2016;11(3):306–25. 10.1097/COH.0000000000000274 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref015] 15.Yin MT, Overton ET. Increasing clarity on bone loss associated with antiretroviral initiation. Journal of Infectious Diseases. 2011;203(12):1705–7. [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref016] 16.Kim H-S, Chin BS, Shin H-S. Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine. Journal of Korean medical science. 2013;28(6):827–32. 10.3346/jkms.2013.28.6.827 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref017] 17.Wandera B, Kiragga A, Semitala F, Ellis J, Colebunders R, Paton N, et al. Low Bone Mineral Density among Ugandan HIV infected patients on failing first line Antiretroviral Therapy; a sub-study of the EARNEST trial. Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections Boston, MA March 3–6, 2014 Boston, MA: National AIDS Treatment Advocavy project; 2014 [http://www.natap.org/2014/CROI/croi_65.htm.

[pone.0246389.ref018] 18.Masyeni S, Utama S, Somia A, Widiana R, Merati TP. Factors influencing bone mineral density in ARV-naive patients at Sanglah Hospital, Bali. Acta Med Indones. 2013;45(3):175–9. [PubMed] [Google Scholar]

[pone.0246389.ref019] 19.Chisati EM, Constantinou D, Lampiao F. Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors. PloS one. 2020;15(1):e0227893 10.1371/journal.pone.0227893 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref020] 20.2019 ISCD Official Positions: Adult: International Society for Clinical Densitometry; 2019 [https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/.

[pone.0246389.ref021] 21.Nwaka S, Ochem A, Besson D, Ramirez B, Fakorede F, Botros S, et al. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent. BMC international health and human rights. 2012;12(1):11 10.1186/1472-698X-12-11 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref022] 22.Castelnuovo B, Kiragga A, Musaazi J, Sempa J, Mubiru F, Wanyama J, et al. Outcomes in a cohort of patients started on antiretroviral treatment and followed up for a decade in an urban clinic in Uganda. PloS one. 2015;10(12):e0142722 10.1371/journal.pone.0142722 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref023] 23.National Health and Nutrition Examination Survey (NHANES) [https://www.cdc.gov/nchs/nhanes/index.htm.

[pone.0246389.ref024] 24.Czerwiński E, Badurski J, Marcinowska-Suchowierska E, Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortopedia, traumatologia, rehabilitacja. 2006;9(4):337–56. [PubMed] [Google Scholar]

[pone.0246389.ref025] 25.WHO, editor World Health Organisation (WHO) scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report; 2004.

[pone.0246389.ref026] 26.Castelnuovo B, Kiragga A, Afayo V, Ncube M, Orama R, Magero S, et al. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa. PloS one. 2012;7(12):e51631 10.1371/journal.pone.0051631 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref027] 27.Fox J, Andersen R. Using the R statistical computing environment to teach social statistics courses. Department of Sociology, McMaster University. 2005:2–4.

[pone.0246389.ref028] 28.Goodrich B, Gabry J, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. 2018.

[pone.0246389.ref029] 29.Bürkner P-C. Advanced Bayesian Multilevel Modeling with the R Package brms. The R Journal. 2018;10(1):395–411. [Google Scholar]

[pone.0246389.ref030] 30.Bürkner P-C. brms: An R Package for Bayesian Multilevel Models Using Stan. Journal of Statistical Software. 2017;80(1):1–28. [Google Scholar]

[pone.0246389.ref031] 31.Zhou B-F, China CM-AGotWGoOi. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and environmental sciences: BES. 2002;15(1):83 [PubMed] [Google Scholar]

[pone.0246389.ref032] 32.Ogunlade O, Adalumo O, Asafa M. Challenges of body mass index classification: New criteria for young adult Nigerians. Nigerian Journal of Health Sciences. 2015;15(2):71. [Google Scholar]

[pone.0246389.ref033] 33.Rahman M, Berenson AB. Accuracy of current body mass index obesity classification for white, black and Hispanic reproductive-age women. Obstetrics and gynecology. 2010;115(5):982 10.1097/AOG.0b013e3181da9423 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref034] 34.Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893–7. 10.1016/j.bone.2005.11.001 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref035] 35.Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS (London, England). 2009;23(12):1519 10.1097/QAD.0b013e32832c1792 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref036] 36.International OSteoporosis Foundation: Official positions Adults 2019 [https://iscd.app.box.com/s/5r713cfzvf4gr28q7zdccg2i7169fv86.

[pone.0246389.ref037] 37.Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. Journal of Clinical Densitometry. 2004;7(1):1–5. 10.1385/jcd:7:1:1 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref038] 38.Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM. Official positions of the International Society for Clinical Densitometry and executive summary of the 2005 Position Development Conference. Journal of Clinical Densitometry. 2006;9(1):4–14. 10.1016/j.jocd.2006.05.002 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref039] 39.Kanis J, Cooper C, Rizzoli R, Reginster J-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3–44. 10.1007/s00198-018-4704-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref040] 40.Sheu A, Diamond T. Diagnostic tests: bone mineral density: testing for osteoporosis. Australian prescriber. 2016;39(2):35 10.18773/austprescr.2016.020 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref041] 41.Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, et al. Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis. Journal of acquired immune deficiency syndromes (1999). 2016;71(3):287 10.1097/QAI.0000000000000858 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref042] 42.Collins BN, Levin KP, Bryant-Stephens T. Pediatricians’ practices and attitudes about environmental tobacco smoke and parental smoking. The Journal of pediatrics. 2007;150(5):547–52. 10.1016/j.jpeds.2007.01.006 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref043] 43.Grant PM, Cotter AG. Tenofovir and bone health. Current Opinion in HIV and AIDS. 2016;11(3):326 10.1097/COH.0000000000000248 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref044] 44.Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. The Journal of infectious diseases. 2015;212(8):1241–9. 10.1093/infdis/jiv194 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref045] 45.McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. Journal of Infectious Diseases. 2011;203(12):1791–801. 10.1093/infdis/jir188 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref046] 46.Bolland MJ, Grey A, Reid IR. Skeletal health in adults with HIV infection. The lancet Diabetes & endocrinology. 2015;3(1):63–74. 10.1016/S2213-8587(13)70181-5 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref047] 47.Hoy JF, Grund B, Roediger M, Schwartz AV, Shepherd J, Avihingsanon A, et al. Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial. Journal of bone and mineral research. 2017;32(9):1945–55. 10.1002/jbmr.3183 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref048] 48.Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clinical infectious diseases. 2013;57(10):1483–8. 10.1093/cid/cit538 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref049] 49.Ofotokun I, Titanji K, Vikulina T, Roser-Page S, Yamaguchi M, Zayzafoon M, et al. Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nature communications. 2015;6(1):1–15. 10.1038/ncomms9282 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref050] 50.Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Aids. 2009;23(7):817–24. 10.1097/QAD.0b013e328328f789 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref051] 51.Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clinical endocrinology. 2012;76(5):643–8. 10.1111/j.1365-2265.2011.04274.x [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref052] 52.Bolland MJ, Horne AM, Briggs SE, Thomas MG, Reid IR, Gamble GD, et al. Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. Calcified tissue international. 2019;105(4):423–9. 10.1007/s00223-019-00579-0 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref053] 53.Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk. Journal of Biological Chemistry. 2003;278(48):48251–8. 10.1074/jbc.M304676200 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref054] 54.Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. The Lancet HIV. 2015;2(11):e464–e73. 10.1016/S2352-3018(15)00181-2 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref055] 55.Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA: the journal of the American Medical Association. 2004;292(2):191–201. 10.1001/jama.292.2.191 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref056] 56.Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–72. 10.1086/656417 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref057] 57.Assoumou L, Katlama C, Viard J-P, Bentata M, Simon A, Roux C, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27(15):2425–30. 10.1097/QAD.0b013e32836378c3 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref058] 58.Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, et al. Less bone loss with maraviroc-compared to tenofovir-containing antiretroviral therapy in the ACTG A5303 Study. Clinical Infectious Diseases. 2015:civ455. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref059] 59.Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, et al. Short communication Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antiviral therapy. 2008;13:1077–82. [PubMed] [Google Scholar]

[pone.0246389.ref060] 60.Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Laboratory investigation. 2009;89(5):513–9. 10.1038/labinvest.2009.14 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref061] 61.Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Aids. 2007;21(10):1273–81. 10.1097/QAD.0b013e3280b07b33 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref062] 62.Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23(6):689–96. 10.1097/QAD.0b013e3283262a64 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref063] 63.Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009;51(5):554–61. 10.1097/QAI.0b013e3181adce44 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref064] 64.Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clinical Infectious Diseases. 2006;42(2):283–90. 10.1086/499048 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref065] 65.Wang MW-H, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. The Journal of clinical investigation. 2004;114(2):206–13. 10.1172/JCI15797 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref066] 66.Steenhoff AP, Schall JI, Samuel J, Seme B, Marape M, Ratshaa B, et al. Vitamin D₃ supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial. PloS one. 2015;10(2):e0117123 10.1371/journal.pone.0117123 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref067] 67.Hidron AI, Hill B, Guest JL, Rimland D. Risk Factors for Vitamin D Deficiency among Veterans with and without HIV Infection. PloS one. 2015;10(4):e0124168 10.1371/journal.pone.0124168 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref068] 68.Wohl D, Doroana M, Orkin C, Pilotto J, Sungkanuparph S, Yeni P, et al., editors. Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial. 18th Conference on Retroviruses and Opportunistic Infections; 2011.

[pone.0246389.ref069] 69.Wiboonchutikul S, Sungkanuparph S, Kiertiburanakul S, Chailurkit L-O, Charoenyingwattana A, Wangsomboonsiri W, et al. Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting. Journal of the International Association of Physicians in AIDS Care (JIAPAC). 2012:1545109711432142. [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref070] 70.Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder. BioMed research international. 2015;2015. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref071] 71.Havers F, Smeaton L, Gupte N, Detrick B, Bollinger RC, Hakim J, et al. 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. Journal of Infectious Diseases. 2014;210(2):244–53. 10.1093/infdis/jiu259 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref072] 72.Dave JA, Cohen K, Micklesfield LK, Maartens G, Levitt NS. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans. PloS one. 2015;10(12):e0144286 10.1371/journal.pone.0144286 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref073] 73.Paul T, Asha H, Thomas N, Seshadri M, Rupali P, Abraham O, et al. Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy. Endocrine Practice. 2010. [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref074] 74.Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31. 10.1097/QAD.0b013e32835192ae [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref075] 75.Cassetti I, Madruga JVR, Suleiman JMA, Etzel A, Zhong L, Cheng AK, et al. The safety and efficacy of tenofovir df in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1—infected patients. HIV clinical trials. 2007;8(3):164–72. 10.1310/hct0803-164 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref076] 76.Madeddu G, Spanu A, Solinas P, Babudieri S, Calia G, Lovigu C, et al. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2015;19(23):4576–89. [PubMed] [Google Scholar]

[pone.0246389.ref077] 77.Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. Aids. 2001;15(10):1275–80. 10.1097/00002030-200107060-00009 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref078] 78.Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. The Journal of Clinical Endocrinology & Metabolism. 2006;91(8):2938–45. 10.1210/jc.2006-0127 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref079] 79.Palermo A, Tuccinardi D, Defeudis G, Watanabe M, D’Onofrio L, Lauria Pantano A, et al. BMI and BMD: the potential interplay between obesity and bone fragility. International journal of environmental research and public health. 2016;13(6):544 10.3390/ijerph13060544 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0246389.ref080] 80.De Laet C, Kanis J, Odén A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporosis international. 2005;16(11):1330–8. 10.1007/s00198-005-1863-y [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref081] 81.Langlois J, Mussolino M, Visser M, Looker A, Harris T, Madans J. Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study. Osteoporosis international. 2001;12(9):763–8. 10.1007/s001980170053 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref082] 82.Ensrud KE, Fullman RL, Barrett-Connor E, Cauley JA, Stefanick ML, Fink HA, et al. Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study. The Journal of Clinical Endocrinology & Metabolism. 2005;90(4):1998–2004. 10.1210/jc.2004-1805 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref083] 83.Bleicher K, Cumming RG, Naganathan V, Travison TG, Sambrook PN, Blyth FM, et al. The role of fat and lean mass in bone loss in older men: findings from the CHAMP study. Bone. 2011;49(6):1299–305. 10.1016/j.bone.2011.08.026 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref084] 84.Compston J, Laskey M, Croucher P, Coxon A, Kreitzman S. Effect of diet-induced weight loss on total body bone mass. Clinical Science. 1992;82(4):429–32. 10.1042/cs0820429 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref085] 85.Center JR, White CP. Obesity: bariatric surgery, weight loss and bone. Nature Reviews Endocrinology. 2013;9(11):630 10.1038/nrendo.2013.189 [DOI] [PubMed] [Google Scholar]

[pone.0246389.ref086] 86.Meyer HE, Søgaard AJ, Falch JA, Jørgensen L, Emaus N. Weight change over three decades and the risk of osteoporosis in men: the Norwegian Epidemiological Osteoporosis Studies (NOREPOS). American journal of epidemiology. 2008;168(4):454–60. 10.1093/aje/kwn151 [DOI] [PubMed] [Google Scholar]

PERMALINK

Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda

Erisa Sabakaki Mwaka

Ian Guyton Munabi

Barbara Castelnuovo

Arvind Kaimal

William Kasozi

Andrew Kambugu

Philippa Musoke

Elly Katabira

Roles

Abstract

Background

Methods

Results

Conclusion

Introduction

Materials and methods

Study design and setting

Fig 1. Participant recruitment.

Study procedures

Data collection and statistical analysis

Results

Table 1. Descriptive statistics for the study population.

Table 2. Showing the correlations between the study variables.

Fig 2. ART treatment at each treatment switch.

Table 3. Univariable and multivariable bone mass models.

Discussion

Strength of the study

Limitations

Conclusion

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Osama Farouk

Roles

Author response to Decision Letter 0

Decision Letter 1

Osama Farouk

Roles

Author response to Decision Letter 1

Decision Letter 2

Osama Farouk

Roles

Acceptance letter

Osama Farouk

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases